Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGS To Focus On “Core Pipeline” As Part Of Cost-Cutting; CEO Steps Down

Executive Summary

Human Genome Sciences is implementing a cost reduction program to focus its resources on clinical development of its immunology/infectious disease and oncology drug candidates
Advertisement

Related Content

R&D Should Be Outsourced Overseas To Control Development Costs – HGS CEO
R&D Should Be Outsourced Overseas To Control Development Costs – HGS CEO
Second Continuous Marketing Application Pilot Program Is 44% Enrolled
Second Continuous Marketing Application Pilot Program Is 44% Enrolled
Advertisement
UsernamePublicRestriction

Register

PS043622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel